{"ResultCount":34,"UpcomingEventsResultCount":0,"HasMoreResults":true,"UpcomingEventsHasMoreResults":false,"GridData":[{"ID":"00000000-0000-0000-0000-000000000000","Category":"Advisories","DisplayDate":"January 24, 2022","DisplayMonth":null,"DisplayDay":null,"Title":"Food & Beverage / FDA Advisory: Bringing Dietary Supplements to Market: Key Requirements and Best Practices","QorusEventTitle":null,"Summary":"Whether you are looking to enter the market or grow your footprint in the industry, you need to know what regulations are relevant and how to prepare to bring a dietary supplement to market. Our Food & Beverage and FDA teams explore the best practices for you to follow and avenues toward approval and success. ","Source":"","SourceUrl":"/-/media/files/insights/publications/2022/01/bringing-dietary-supplements-to-market.pdf?sc_lang=en","BackgroundImageUrl":null,"BackgroundImageAlt":null,"VideoEmbed":null,"NavigateLink":{"Url":"/en/insights/publications/2022/01/bringing-dietary-supplements-to-market","Title":"Food & Beverage / FDA Advisory: Bringing Dietary Supplements to Market: Key Requirements and Best Practices","Target":"","CssClass":"","IsActive":false},"TemplateID":"00000000-0000-0000-0000-000000000000","HasContent":true,"Url":null,"City":null,"Street":null,"PostalCode":null,"State":null,"IsExternalLink":false},{"ID":"00000000-0000-0000-0000-000000000000","Category":"Advisories","DisplayDate":"April 20, 2021","DisplayMonth":null,"DisplayDay":null,"Title":"FDA Compliance & Enforcement Advisory: FDA Issues New Guidance on Remote Interactive Evaluations for Oversight of Drug Facilities","QorusEventTitle":null,"Summary":"

Our FDA Compliance & Enforcement Team examines the Food and Drug Administration’s first guidance on remote interactive evaluations, a tool in response to the agency’s COVID-19 inspection postponements.

","Source":"","SourceUrl":"/-/media/files/insights/publications/2021/04/remote-interactive-evals.pdf?sc_lang=en","BackgroundImageUrl":null,"BackgroundImageAlt":null,"VideoEmbed":null,"NavigateLink":{"Url":"/en/insights/publications/2021/04/fda-issues-new-guidance-on-remote","Title":"FDA Compliance & Enforcement Advisory: FDA Issues New Guidance on Remote Interactive Evaluations for Oversight of Drug Facilities","Target":"","CssClass":"","IsActive":false},"TemplateID":"00000000-0000-0000-0000-000000000000","HasContent":true,"Url":null,"City":null,"Street":null,"PostalCode":null,"State":null,"IsExternalLink":false},{"ID":"00000000-0000-0000-0000-000000000000","Category":"Advisories","DisplayDate":"April 16, 2021","DisplayMonth":null,"DisplayDay":null,"Title":"Products Liability / Litigation Advisory: How Will Supreme Court’s New Decision on Personal Jurisdiction Impact Manufacturers?","QorusEventTitle":null,"Summary":"Defendants and lower courts hoping for clarity about personal jurisdiction were disappointed by the U.S. Supreme Court last month. Our Products Liability and Litigation Groups examine a new decision whose ambiguity could invite more litigation despite a high bar for specific jurisdiction.
","Source":"","SourceUrl":"/-/media/files/insights/publications/2021/04/how-will-supreme-courts-new-decision-on-personal-j.pdf?sc_lang=en","BackgroundImageUrl":null,"BackgroundImageAlt":null,"VideoEmbed":null,"NavigateLink":{"Url":"/en/insights/publications/2021/04/supreme-court-decision-personal-jurisdiction","Title":"Products Liability / Litigation Advisory: How Will Supreme Court’s New Decision on Personal Jurisdiction Impact Manufacturers?","Target":"","CssClass":"","IsActive":false},"TemplateID":"00000000-0000-0000-0000-000000000000","HasContent":true,"Url":null,"City":null,"Street":null,"PostalCode":null,"State":null,"IsExternalLink":false},{"ID":"00000000-0000-0000-0000-000000000000","Category":"Advisories","DisplayDate":"December 22, 2020","DisplayMonth":null,"DisplayDay":null,"Title":"Food & Beverage / FDA Advisory: Generally Recognized as Safe: Establishing a Suitable U.S. Regulatory Status for Food Ingredients","QorusEventTitle":null,"Summary":"What are the benefits and drawbacks of coming to an independent generally recognized as safe (GRAS) conclusion for a novel food ingredient compared to filing a GRAS notification with the FDA? Our Food & Beverage and FDA teams provide insight into the FDA’s GRAS regulatory pathway as a continuation of this series exploring best practices for premarket food approval.","Source":"","SourceUrl":"/-/media/files/insights/publications/2020/12/generally-recognized-as-safe--establishing-a-suita.pdf?sc_lang=en","BackgroundImageUrl":null,"BackgroundImageAlt":null,"VideoEmbed":null,"NavigateLink":{"Url":"/en/insights/publications/2020/12/food-beverage-fda-advisory-generally-recognized-as","Title":"Food & Beverage / FDA Advisory: Generally Recognized as Safe: Establishing a Suitable U.S. Regulatory Status for Food Ingredients","Target":"","CssClass":"","IsActive":false},"TemplateID":"00000000-0000-0000-0000-000000000000","HasContent":true,"Url":null,"City":null,"Street":null,"PostalCode":null,"State":null,"IsExternalLink":false},{"ID":"00000000-0000-0000-0000-000000000000","Category":"Advisories","DisplayDate":"November 6, 2020","DisplayMonth":null,"DisplayDay":null,"Title":"Food & Beverage / FDA Advisory: Strategic Approaches for Establishing a Suitable U.S. Regulatory Status for Food Ingredients and Dietary Supplements","QorusEventTitle":null,"Summary":"What does it take to clear regulatory hurdles to bring food and drugs to market? Our Food & Beverage and FDA teams begin a series exploring best practices for you to follow and the many avenues to approval and success. First: laying the foundation.
\n

","Source":"","SourceUrl":"/-/media/files/insights/publications/2020/11/regulatory-status-for-food-ingredients-and-dietary.pdf?sc_lang=en","BackgroundImageUrl":null,"BackgroundImageAlt":null,"VideoEmbed":null,"NavigateLink":{"Url":"/en/insights/publications/2020/11/regulatory-status-for-food-ingredients","Title":"Food & Beverage / FDA Advisory: Strategic Approaches for Establishing a Suitable U.S. Regulatory Status for Food Ingredients and Dietary Supplements","Target":"","CssClass":"","IsActive":false},"TemplateID":"00000000-0000-0000-0000-000000000000","HasContent":true,"Url":null,"City":null,"Street":null,"PostalCode":null,"State":null,"IsExternalLink":false},{"ID":"00000000-0000-0000-0000-000000000000","Category":"Advisories","DisplayDate":"September 21, 2020","DisplayMonth":null,"DisplayDay":null,"Title":"FDA Compliance & Enforcement Advisory: FDA Issues New Guidance on Nitrosamine Impurities in APIs and Drug Products","QorusEventTitle":null,"Summary":"Our FDA Compliance & Enforcement Team reviews how the Food and Drug Administration’s first guidance on nitrosamine impurities shows what the FDA has learned about the sources of such impurities and what manufacturers can do to prevent unacceptable levels of them.
\n

","Source":"","SourceUrl":"/-/media/files/insights/publications/2020/09/fda-issues-new-guidance-on-nitrosamine-impurities.pdf?sc_lang=en","BackgroundImageUrl":null,"BackgroundImageAlt":null,"VideoEmbed":null,"NavigateLink":{"Url":"/en/insights/publications/2020/09/fda-issues-new-guidance-on-nitrosamine","Title":"FDA Compliance & Enforcement Advisory: FDA Issues New Guidance on Nitrosamine Impurities in APIs and Drug Products","Target":"","CssClass":"","IsActive":false},"TemplateID":"00000000-0000-0000-0000-000000000000","HasContent":true,"Url":null,"City":null,"Street":null,"PostalCode":null,"State":null,"IsExternalLink":false},{"ID":"00000000-0000-0000-0000-000000000000","Category":"Advisories","DisplayDate":"September 14, 2020","DisplayMonth":null,"DisplayDay":null,"Title":"Food, Drug & Device/FDA Advisory: An Old Drug for a New Emergency: FDA Issues New Guidance on the Use of Convalescent Plasma for COVID-19","QorusEventTitle":null,"Summary":"The Food and Drug Administration released guidance for the use of convalescent plasma to treat COVID-19 to supplement its recently issued emergency use authorization. Our Food, Drug & Device/FDA Team analyzes the specifics of when and how convalescent plasma can be used and how the FDA will enforce compliance.
\n

","Source":"","SourceUrl":"/-/media/files/insights/publications/2020/09/plasma--an-old-drug-for-a-new-emergency.pdf?sc_lang=en","BackgroundImageUrl":null,"BackgroundImageAlt":null,"VideoEmbed":null,"NavigateLink":{"Url":"/en/insights/publications/2020/09/an-old-drug-for-a-new-emergency","Title":"Food, Drug & Device/FDA Advisory: An Old Drug for a New Emergency: FDA Issues New Guidance on the Use of Convalescent Plasma for COVID-19","Target":"","CssClass":"","IsActive":false},"TemplateID":"00000000-0000-0000-0000-000000000000","HasContent":true,"Url":null,"City":null,"Street":null,"PostalCode":null,"State":null,"IsExternalLink":false},{"ID":"00000000-0000-0000-0000-000000000000","Category":"Press Release","DisplayDate":"August 21, 2020","DisplayMonth":null,"DisplayDay":null,"Title":"Alston & Bird Earns Broad Recognition in 2021 Best Lawyers and Ones to Watch","QorusEventTitle":null,"Summary":"Two hundred and nineteen Alston & Bird attorneys have been selected by their peers for inclusion in the 2021 edition of The Best Lawyers in America©, and 69 attorneys have been selected for the inaugural edition of Best Lawyers: Ones to Watch.","Source":null,"SourceUrl":null,"BackgroundImageUrl":null,"BackgroundImageAlt":null,"VideoEmbed":null,"NavigateLink":{"Url":"/en/insights/news/2020/08/best-lawyers-2021","Title":"Alston & Bird Earns Broad Recognition in 2021 Best Lawyers and Ones to Watch","Target":"","CssClass":"","IsActive":false},"TemplateID":"00000000-0000-0000-0000-000000000000","HasContent":true,"Url":null,"City":null,"Street":null,"PostalCode":null,"State":null,"IsExternalLink":false},{"ID":"00000000-0000-0000-0000-000000000000","Category":"Advisories","DisplayDate":"May 4, 2020","DisplayMonth":null,"DisplayDay":null,"Title":"Food, Drug & Device/FDA Advisory: Examining the Drug Supply Chain – How the Public Health Emergency Impacts DSCSA","QorusEventTitle":null,"Summary":"The Drug Supply Chain Security Act was intended to enhance the safety and security of the pharmaceutical distribution supply chain – but in a few short months, everything has changed. Our Food, Drug & Device/FDA Group examines the Food and Drug Administration’s latest guidance and the state of DSCSA requirements during the coronavirus (COVID-19) pandemic.
\n

","Source":"","SourceUrl":"/-/media/files/insights/publications/2020/05/examining-the-drug-supply-chain.pdf?sc_lang=en","BackgroundImageUrl":null,"BackgroundImageAlt":null,"VideoEmbed":null,"NavigateLink":{"Url":"/en/insights/publications/2020/05/examining-the-drug-supply-chain","Title":"Food, Drug & Device/FDA Advisory: Examining the Drug Supply Chain – How the Public Health Emergency Impacts DSCSA","Target":"","CssClass":"","IsActive":false},"TemplateID":"00000000-0000-0000-0000-000000000000","HasContent":true,"Url":null,"City":null,"Street":null,"PostalCode":null,"State":null,"IsExternalLink":false},{"ID":"00000000-0000-0000-0000-000000000000","Category":"FDA Compliance & Enforcement Advisory","DisplayDate":"April 9, 2020","DisplayMonth":null,"DisplayDay":null,"Title":"FDA Compliance & Enforcement Advisory: FDA Issues New Guidance on Supply-Chain Disruption Notifications During COVID-19 Emergency","QorusEventTitle":null,"Summary":"Government-enforced shutdowns and quarantines overseas have interrupted life-saving drug manufacturing, affecting the country’s ability to fight COVID-19. Our FDA Compliance & Enforcement Team reviews how the Food and Drug Administration is reassessing how drug suppliers facing supply disruptions need to notify the agency.","Source":"","SourceUrl":"/-/media/files/insights/publications/2020/04/fda-issues-new-guidance-on-supplychain-disruption.pdf?sc_lang=en","BackgroundImageUrl":null,"BackgroundImageAlt":null,"VideoEmbed":null,"NavigateLink":{"Url":"/en/insights/publications/2020/04/fda-issues-new-guidance-on-supply-chain-disruption","Title":"FDA Compliance & Enforcement Advisory: FDA Issues New Guidance on Supply-Chain Disruption Notifications During COVID-19 Emergency","Target":"","CssClass":"","IsActive":false},"TemplateID":"00000000-0000-0000-0000-000000000000","HasContent":true,"Url":null,"City":null,"Street":null,"PostalCode":null,"State":null,"IsExternalLink":false}],"UpcomingEvents":[],"PastEvents":[],"PinnedInsights":[],"SearchFilters":{"PageGuid":"0ec44407-7860-4d02-8f70-466012aea43a","Skip":0,"Take":10,"InitialPageSize":0,"ReloadFilters":false,"SeparateUpcomingEvents":false,"KeywordFilter":"","DateFrom":"2012-10-02T07:48:06.9423933Z","DateTo":"2022-11-27T02:48:06.9423933","EntityFilter":{"ID":"0ec44407-7860-4d02-8f70-466012aea43a","PublicationTypeID":"00000000-0000-0000-0000-000000000000","Name":"Hergenrother, Jenny","Url":"","IsSelected":false,"IsEnabled":true,"Filter":[],"ParentName":""},"PracticeFilters":[],"IndustryFilters":[],"TypeFilters":[],"ArticleTypeFilters":[],"OtherFilters":[],"PastDateFilters":[],"FutureDateFilters":[],"NewsTypeFilters":[],"EventTypeFilters":[],"PublicationTypeFilters":[],"BlogTypeFilters":[],"OfficeFilters":[]}}

Bar Admissions

Education

Memberships